Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I think we can figure out why our former CEO bolted so quickly. I rest my case for my last six years of commentary. Since the housecleaning has begun, let's take a look at the BOD. The whole regulatory process, from BOD supervision to a supposed law firm in DC that was supposedly advising the company, was less than stellar. Time is of the essence right now. We need the 510, and then it's really up to our BOD to begin the marketing process in the U.S.
I think your reference to the lack of execution is pertinent on all issues related to this company. What we're wringing our hands over now should have been settled 3-5 years ago. Testing is paramount to success. Test results will be the company's business card and marketing arm. Hospital insurers should be among the first groups to know about AS. Why no testing has been reported(or begun)after 3+ months is a testament to the history of prior management. We must be a bit patient and allow new management time to untangle the web and establish some credibility with institutions that the company has never enjoyed.
a 5 cent spread on a 40 cent stock that has turned over a whopping $13,600 in total trading volume is not unusual. Hopefully the market makers controlling GTHP also control some other issues so they won't starve.
Updated stats from around the world and a new lead FDA reviewer who is a female OB/GYN by trade could make a difference.
Maybe a little action from our new interim CEO will remind us how little action we ever had from the former CEO. No awareness programs were ever put into place....that's for sure.
At this point, one has to weigh the alternative.....which is "Out of Business". The bright side is that an investor group has taken a 7% stake in the company. Given the company prospects without that stake, I would think the investment group would be entitled to a few perks along the way. Now, at least, there might be funds to readdress the FDA and get LV moving over here.
Onward and upward. There is no super-ego here. D.E. is not beyond accepting help to connect him with entities, like foundations, that concentrate on eradicating illnesses and alleviating suffering around the globe.
Our immediate former CEO reminded us at the December meeting in SLC that DE had sold a company previously and had made a tidy sum for everyone. I will remind everyone that DE also was in charge of operations of that other company at the time. What shareholders receive ultimately from Medizone depends on what kind of value can be created for the company. Right now the marketplace, in spite of all the current good news, tells us it's worth fourteen cents per share. Market research, a true business plan, demonstrations (aka testing), sales penetration in multiple markets, and a relentless staff pursuing merger partners, will tell the tale.
Oh.....well......maybe we did do a little good last summer. My thanks go out to everyone who participated in the conference calls. We can assume the calls were attended by a few people who remained anonymous and quiet. I also relayed your collective efforts to a few individuals "in the loop" who attended the meeting in SLC. So...thanks again to all the participants.
For what?
Okay.....permit me to reword a little commentary. EPA approval is done. Let's say there is no publication of results concerning primary testing of AS in hospitals in California or anywhere else by the end of April. Would management's supporters, who wanted to wait out 2016 for EPA approval before voting for change, still be inclined to vote for the continuation of the old Board if an emergency shareholder meeting was convened? What's left to make them want to maintain the status quo?
What I was getting at was the fact that the science seems to work beautifully. Advanced portability and mobility would bring it a long way forward, but it has to be in the hands of an assembler capable of downsizing it without sacrificing efficiency.
The historical commentary speaks for itself. The product is fine. What we have never had is formal promotion of the science to the scientific and business community: neither awareness nor marketing programs exist, and the world is still unfamiliar with AS. Here's my bottom line: We were promised a hospital test in California this winter. Let's give it till mid-late March to materialize. Should nothing develop, we already have a shareholder network in place, in order to mobilize, from last year's conference calls. We will pledge enough shares to demand another shareholder meeting, and, this time, since the almighty EPA approval has been given, previously reluctant shareholders who wanted to "wait it out" last year now will have nothing left on which to hang their hats. It will be time to ask all shareholders to do the right thing for the company, its shareholders, and the healthcare community.
The only concern I have ever had with the technology was a portability issue....for everything from cruise line cabins to airline restrooms, etc. Science, over time, creates portability everywhere else, and, in the right hands, AS could be there by now.
Hey Hey Hey Hey....Never......watch it when it comings to demeaning the Stooges!
Once again, shareholders are paying Corporate Communications to NOT communicate with us...just like in December when the company directly refused to engage shareholders.
History has taught many of us to disregard the rhetoric and keep an eye on the deed. The recent shareholder meeting did little/nothing to instill confidence in this team going forward. We were promised an actual hospital test in January. We await the reality of that situation.
Trump's preferred choice to head the FDA is Jim O'Neil. Two of Trump's three top picks for this post have credentials embracing prevention. We should get familiar with the term "geroprotection". Asepticsure is about as prevention oriented as we could ever hope a decontamination system to be. We need to remind ourselves that AS can be used to prevent HAIs and not just react to disease breakouts. Today is February 1. Testing anyone? Anywhere? Has our CEO gone to the office this week and, if so, did he engage in meaningful activities to promote AS?
Well, in order to justify a press release, a company must have something on which to report. Today is January 30. Given company history, I would suspect that no testing has been conducted so far.
You're assuming that Medizone had developed an awareness program for Asepticsure after the patents were granted and initial testing proved positive. The company feigned to get angry with shareholders who might actually tell someone at a healthcare business about Asepticsure. It turns out that, in most cases, that's the only way a facility would have found out about it.
Red Diamond is a diversified, privately held, private equity company. It has been around a while. Yes, it can have a habit of trying to help "distressed" companies while saddling said companies with exorbitant debt and equity service. Unfortunately, when a company is as cash strapped as GTHPD is cash strapped, then few alternatives exist. I would give this venture, based on history, about a 20% chance for success and only if GTHPD is on the verge of cracking into some major foreign markets plus getting back with the FDA.
Yes, Moon, involvement from Esposito and Caponi are life sustaining measures going forward. Why testing wasn't begun in hospitals five years ago is beyond me. We should have had an army of test results as proof by 12-31-16. Alas, Medizone cannot afford another week of wasted time. The world remains ignorant of AS and its life-saving properties. An awareness program, also needed five years ago, should be implemented immediately. Future press releases should go way beyond the company website and Yahoo. Established global distributors of medical devices and related products should be in the loop. Obviously the list of items needing immediate attention continues to grow.
Value has to be created. It doesn't appear out of thin air. If Esposito was able to sell a company at an enviable price in the past, it's because he had the position and authority to build the company and thus create the value. That's all I ask: I want our CEO to go to work every day and promote Medizone to the world.
Oooops...my error. I'll have to check my notes. Thanks for the heads up.
Permit me to elaborate on Surfski's report. IHUB was shut down to me for three days. I probably traveled the farthest distance of anyone and took some extra time to hang out with a high school buddy in SLC. WIV, Surfski, MzeiToTheMoon, and I got acquainted, and that part of it was the most fun we had. Had the votes not been counted at that time, I am confident the four of us could have demanded an audience and kept the meeting going for several more hours. Voting, however, was strained. The huge number of abstentions may be telling everyone that regime support is waning.
The meeting was what many of you feared it was going to be: SameO. SameO. I am trying to feel embarrassed for Esposito, especially if he was unaware of the CEO's commentary before it was delivered. Management remains adamant about establishing a formal business/marketing plan, even though those plans have been taught in every MBA program from Harvard to Stanford for the last 100 years.....
I hope Esposito can find his way to really take over the running of the business. We need an engaged CEO who actually shows up for work in the morning. I had a good chat with Doc Shannon. He is a scientific genius and, IMHO, is just not getting the business support he needs.
No mention was made of the CEO's medical condition that was alluded to here on IHUB recently. No one was identifiable from the Florida Group....the bunch that voted back in the status quo.
There's not much left to say, so I will end my commentary and bid you all Happy Holidays.
When one studies the martial arts, one quickly learns that a loss of temper disrupts strategy and renders half the battle lost. Calm will prevail, and pertinent questions will be asked......with a smile.
History, and my gut, tell me that shareholders should not assume any level of activity until they get clarifications from this meeting. The duration could be lengthy, and shareholders will expect tough questions to be fielded. Attendees will be seeking tangible answers.
Thanks, Spike 27. It's easy to want to help minority shareholders when their informational needs go unmet for seven years. Make sure hats get tipped for WIV. He dissected the situations that came up and kept his results within the realm of current realities instead of the realm of wishful dreaming.
Your "two cents" are greatly appreciated. Knowing what to do and acting on it remain two totally different aspects of this situation.
I will repeat myself that EPA approval should make shareholders go back and take a second look at all the proxies. I expect shareholders to approve the increase in authorized common shares. Why then does management need to keep the preferred stock issue that is an obvious "poison pill" to unsolicited suitors? A buyout is the best solution for shareholders, yet management recommends a vote "against" rescinding the preferred offering. Look at the company infrastructure and tell me how the company plans to go it alone. Where's the plan? While we're re-perusing the proxies, maybe there are a couple of other votes that also could stand to be changed.
EPA approval has made at least one of the shareholder proposals more meaningful. There is a proposal on the books to retire the preferred stock offering. A potential unsolicited suitor would look upon that offering as a deterrent, i.e., a "poison pill" to thwart an attempt to buy the company. Management wants shareholders to vote "against" that proposal. Why would we want to vote it down?
You just "go" Goony. I am hoping for a crowd so large that the meeting will have to be moved to the "Executive Dining Room".
So true, Joe. The question "Now What?" will be on everyone's mind this week. Nothing much has changed. There's still no AS awareness program, and the company is just now getting around to thinking about testing, protocols that should have been established five years ago. "Now what" for Canada?
The way I understand the wording is that the "75 rule" currently applies to Hoyt and would apply to Marshall only if Marshall was no longer an officer.
Yes, Goony, there will be a few people at the meeting who will have the best interests of the shareholders at heart.
It already has happened
symbol change gthpd
GTHPD now has nothing left in its bag of tricks to help it stay afloat. The reverse splits are done for good (there's hardly enough stock left to function, the financing is supposed to be done, and now we wait on news of further sales breakthroughs plus the company's attempt to amend its NDA and get it to the new lead reviewer at the FDA ASAP. A tall order!
I don't think any work has been done on resubmitting the amended PMA. The financing arrangement and accompanying R/S is to be done to create the funds necessary to fund that research. I think we're still 12-18 months away from a U.S. FDA approval.
That's an interesting statement, 17 year man. One could think this situation, if your date is accurate, was known to the BOD before the announcement of the AGM in September......yet no potential changes in succession were addressed for discussion at that September AGM.....or the December AGM we are looking forward to now. So much for succession planning, either at the managerial or the scientific level.